Patents by Inventor Ernest J. Mceachern

Ernest J. Mceachern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140275022
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: June 27, 2012
    Publication date: September 18, 2014
    Applicants: MERCK SHARP & DOHME CORP., ALECTOS THERAPEUTICS INC.
    Inventors: Tong-Shuang Li, Ernest J. Mceachern, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu, Harold G. Selnick
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140213584
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: November 8, 2011
    Publication date: July 31, 2014
    Applicants: Merck Sharp & Dohme Corp., Alectos Therapeutics Inc.
    Inventors: Craig A. Coburn, Kun Liu, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140206665
    Abstract: The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: August 10, 2012
    Publication date: July 24, 2014
    Applicants: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Harold G. Selnick, Kun Liu, Ernest J. McEachern, Yuanxi Zhou, Yongbao Zhu
  • Chemokine receptor binding heterocyclic compounds with enhanced efficacy
    Patent number: 8778967
    Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: July 15, 2014
    Assignee: Genzyme Corporation
    Inventors: Gary Bridger, Renato T Skelj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R Wilson, Jason B Crawford, Ernest J McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria R Di Fluri
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140107044
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: March 16, 2012
    Publication date: April 17, 2014
    Applicants: Merck Sharp & Dohme Corp., Alectos Therapeutics Inc.
    Inventors: Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Craig A. Coburn, Kun Liu, Harold G. Selnick
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140088028
    Abstract: The invention provides compounds of formula (I) with substituents as specified in Claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac.
    Type: Application
    Filed: March 20, 2012
    Publication date: March 27, 2014
    Inventors: Ramesh Kaul, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Kun Liu, Harold G. Selnick, Zhongyong Wei, Changwei Mu, Yaode Wang, Xiaona Wang
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140018309
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: December 21, 2011
    Publication date: January 16, 2014
    Applicants: MERCK SHARP & DOHME CORP., ALECTOS THERAPEUTICS, INC.
    Inventors: Ramesh Kaul, Ernest J. Mceachern, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20130296301
    Abstract: The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: November 8, 2011
    Publication date: November 7, 2013
    Inventors: Jiang Chang, Kun Liu, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, Feng Shi, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20130131044
    Abstract: The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: May 10, 2011
    Publication date: May 23, 2013
    Inventors: Tong-Shuang Li, Ernest J. Mceachern, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu
  • CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY
    Publication number: 20120301427
    Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HW).
    Type: Application
    Filed: January 25, 2012
    Publication date: November 29, 2012
    Inventors: Gary BRIDGER, Al KALLER, Curtis HARWIG, Renato SKERLJ, David BOGUCKI, Trevor R. WILSON, Jason CRAWFORD, Ernest J. MCEACHERN, Bem ATSMA, Siqiao NAN, Yuanxi ZHOU, Dominique SCHOLS, Christopher D. SMITH, Maria R. DI FLURI
  • CXCR4 chemokine receptor binding compounds
    Patent number: 7863293
    Abstract: The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.
    Type: Grant
    Filed: November 6, 2007
    Date of Patent: January 4, 2011
    Assignee: Genzyme Corporation
    Inventors: Gary J. Bridger, Ernest J. McEachern, Renato Skerlj, Dominique Schols, Ian Baird, Al Kaller, Curtis Harwig, Yongbao Zhu, Gang Chen, Krystyna Skupinska
  • CHEMOKINE RECEPTOR BINDING COMPOUNDS
    Publication number: 20100298366
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Application
    Filed: August 5, 2010
    Publication date: November 25, 2010
    Applicant: Genzyme Corporation
    Inventors: Yuanxi ZHOU, Elyse Bourque, Yongbao Zhu, Jonathan Langille, Markus Metz, Wen Yang, Ernest J. Mceachern, Curtis Harwig, Ian R. Baird, Tong-Shuang Li, Renato T. Skerlj
  • Chemokine receptor binding heterocyclic compounds
    Patent number: 7807694
    Abstract: Compounds which modulate chemokine receptor activities are disclosed. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: October 5, 2010
    Assignee: Genzyme Corporation
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
  • Chemokine receptor binding compounds
    Patent number: 7790747
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: September 7, 2010
    Assignee: Genzyme Corporation
    Inventors: Yuanxi Zhou, Elyse Bourque, Yongbao Zhu, Jonathan Langille, Markus Metz, Wen Yang, Ernest J. McEachern, Curtis Harwig, Ian R. Baird, Tong-Shuang Li, Renato T. Skerlj
  • CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS
    Publication number: 20100105915
    Abstract: Heterocyclic compounds that bind chemokine receptors and inhibit the binding of their natural ligands are disclosed. The invention compounds are protective against infection by HIV and exert effects characteristic of antagonists to the CXCR4 receptor.
    Type: Application
    Filed: November 4, 2009
    Publication date: April 29, 2010
    Inventors: Gary J. BRIDGER, Renato Skerlj, Ai Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. Mceachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols
  • Chemokine receptor binding heterocyclic compounds
    Patent number: 7629337
    Abstract: Heterocyclic compounds that bind chemokine receptors and inhibit the binding of their natural ligands are disclosed. The invention compounds are protective against infection by HIV and exert effects characteristic of antagonists to the CXCR4 receptor.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: December 8, 2009
    Assignee: Genzyme Corporation
    Inventors: Gary J. Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols
  • CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY
    Publication number: 20090281308
    Abstract: Compounds that interact with the CXCR4 receptor are described. These compounds are useful in treating, for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in methods to elevate progenitor and stem cell counts as well as methods to elevate white blood cell counts.
    Type: Application
    Filed: May 15, 2009
    Publication date: November 12, 2009
    Inventors: Gary J. BRIDGER, Ernest J. MCEACHERN, Renato SKERLJ, Dominique SCHOLS, Ian BAIRD, Al KALLER, Curtis HARWIG, Yongbao ZHU, Gang CHEN, Krystyna SKUPINSKA, Markus METZ
  • Chemokine receptor binding heterocyclic compounds with enhanced efficacy
    Patent number: 7550484
    Abstract: Compounds that interact with the CXCR4 receptor are described. These compounds are useful in treating, for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in methods to elevate progenitor and stem cell counts as well as methods to elevate white blood cell counts.
    Type: Grant
    Filed: April 22, 2004
    Date of Patent: June 23, 2009
    Assignee: Genzyme Corporation
    Inventors: Gary J. Bridger, Ernest J. McEachern, Renato Skerlj, Dominique Schols, Ian Baird, Al Kaller, Curtis Harwig, Yongbao Zhu, Gang Chen, Krystyna Skupinska, Markus Metz
  • Chemokine receptor binding compounds
    Publication number: 20090099205
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Application
    Filed: June 14, 2006
    Publication date: April 16, 2009
    Inventors: Yuanxi Zhou, Elyse Bourque, Yongbao Zhu, Jonathan Langille, Markus Metz, Wen Yang, Ernest J. McEachern, Curtis Harwig, Ian R. Baird, Tong-Shuang Li, Renato T. Skerlj
  • Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
    Patent number: 7452994
    Abstract: This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)- and (S)-forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)- or (S)-enantiomer of primary amino-substituted fused bicyclic ring systems.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: November 18, 2008
    Assignee: Anormed, Inc.
    Inventors: Ernest J. McEachern, Gary J. Bridger, Krystyna A. Skupinska, Renato T. Skerlj, Wen Yang